Severe skeletal and renal complications in SLC4A1-related distal renal tubular acidosis following prolonged treatment interruption: a case report highlighting transition-related vulnerability
- 1Department of Pediatrics, Beijing Geriatric Hospital, Beijing, China
- 2Department of Pediatrics, Beijing Liang Xiang Hospital, Beijing, China
- 3Department of Respiratory Medicine, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, No. 56 Nanlishi Road, Xicheng District, Beijing, 100045 China
Abstract
Background: SLC4A1-related distal renal tubular acidosis (dRTA), caused by dysfunction of the anion exchanger 1 (AE1), is typically associated with a relatively mild and late-onset phenotype. However, outcomes may vary substantially, particularly in the setting of delayed diagnosis or prolonged interruption of therapy.
Case presentation: We report a 31-year-old woman with genetically confirmed SLC4A1-related dRTA who presented with recurrent nephrolithiasis, urinary tract infections, and severe skeletal deformities. She discontinued alkali therapy for approximately 13 years after childhood diagnosis, resulting in extreme growth retardation (height −6.2 SD) and advanced osteomalacia. Laboratory evaluation revealed severe hyperchloremic metabolic acidosis, hypokalemia, persistently alkaline urine, and mildly reduced renal function consistent with chronic kidney disease (CKD) stage 2. Imaging demonstrated Looser–Milkman pseudofractures, “fish vertebrae,” and nephrocalcinosis with ureteral obstruction requiring double-J stent placement. Genetic testing identified a heterozygous SLC4A1 variant (c.2704G>T, p. Asp902Tyr), classified as likely pathogenic. The patient’s mother, carrying the same variant, exhibited a milder phenotype.
Conclusions: This case illustrates that prolonged interruption of alkali therapy in SLC4A1-related dRTA may result in severe and irreversible skeletal and renal complications, even in genotypes typically considered mild. It highlights the pediatric-to-adult transition as a critical period for treatment discontinuation and underscores the importance of lifelong therapy, early intervention, and long-term follow-up.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12882-026-05213-4.
Related
- PRIMARY GASTRIC PLASMABLASTIC LYMPHOMA FOLLOWING ANTIRETROVIRAL THERAPY INTERRUPTION IN A PATIENT WITH PREVIOUSLY TREATED GASTRIC DIFFUSE LARGE B-CELL LYMPHOMA: A REFRACTORY CASE REPORT
- Secondary (anamnestic) anti D alloimmunization following transfusion of a DEL phenotype rhesus D negative unit: A case report highlighting the need for DEL screening in India.
- Transition from extended to single-dose antibiotic prophylaxis was not associated with increased postoperative infectious complications in urologic surgery
- Complications and management of thyroglossal duct cyst following Sistrunk procedure in children: a single-center retrospective study in Shanghai, China
- Commentary on “Postoperative complications and mechanical outcomes following endoscopic versus open lumbar fusion: a propensity-matched analysis”
BibTeX
@article{gao2026severe,
title = {{Severe skeletal and renal complications in SLC4A1-related distal renal tubular acidosis following prolonged treatment interruption: a case report highlighting transition-related vulnerability}},
author = {Xinying Gao and Nan Bai and Xuejing Sun and Yao Yao},
journal = {BMC Nephrology},
year = {2026},
month = aug,
doi = {10.1186/s12882-026-05213-4},
url = {https://doi.org/10.1186/s12882-026-05213-4},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Severe skeletal and renal complications in SLC4A1-related distal renal tubular acidosis following prolonged treatment interruption: a case report highlighting transition-related vulnerability
AU - Xinying Gao
AU - Nan Bai
AU - Xuejing Sun
AU - Yao Yao
PY - 2026
DA - 2026/08/08
JO - BMC Nephrology
DO - 10.1186/s12882-026-05213-4
UR - https://doi.org/10.1186/s12882-026-05213-4
AB - Background: SLC4A1-related distal renal tubular acidosis (dRTA), caused by dysfunction of the anion exchanger 1 (AE1), is typically associated with a relatively mild and late-onset phenotype. However, outcomes may vary substantially, particularly in the setting of delayed diagnosis or prolonged interruption of therapy. Case presentation: We report a 31-year-old woman with genetically confirmed SLC4A1-related dRTA who presented with recurrent nephrolithiasis, urinary tract infections, and severe skeletal deformities. She discontinued alkali therapy for approximately 13 years after childhood diagnosis, resulting in extreme growth retardation (height −6.2 SD) and advanced osteomalacia. Laboratory evaluation revealed severe hyperchloremic metabolic acidosis, hypokalemia, persistently alkaline urine, and mildly reduced renal function consistent with chronic kidney disease (CKD) stage 2. Imaging demonstrated Looser–Milkman pseudofractures, “fish vertebrae,” and nephrocalcinosis with ureteral obstruction requiring double-J stent placement. Genetic testing identified a heterozygous SLC4A1 variant (c.2704G>T, p. Asp902Tyr), classified as likely pathogenic. The patient’s mother, carrying the same variant, exhibited a milder phenotype. Conclusions: This case illustrates that prolonged interruption of alkali therapy in SLC4A1-related dRTA may result in severe and irreversible skeletal and renal complications, even in genotypes typically considered mild. It highlights the pediatric-to-adult transition as a critical period for treatment discontinuation and underscores the importance of lifelong therapy, early intervention, and long-term follow-up. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12882-026-05213-4.
SN - 1471-2369
ER -